Changing a single DNA base-pair letter of the PCSK9 gene by VERVE-1 infusion significantly reduces LDL in humans. VERVE-1 moves forward to evaluate clinical effect. Watch my interview with Dr. Bellinger and Dr. Kathiresan. shorturl.at/mt057 #AHA23

Excited to share new work from the lab 👇 Longitudinal Control of Lipid Levels in Patients With Premature Corona... sciencedirect.com/science/articl…

🧬 We’re excited to announce that we have sequenced the whole genomes of 500,000 UK Biobank volunteers! 🧬 The dataset is the world’s largest of its kind and we’re proud to make it available to approved researchers around the world 🌍 ow.ly/qsyy50QcJ7w #500KGenomes

We're pleased to announce Dr. Harlan M. Krumholz, a globally esteemed cardiologist and researcher, as the incoming editor-in-chief of #JACC! Join us in celebrating his appointment and learn more about his incredible contributions to the field: bit.ly/3Te9XfF Harlan Krumholz

Congrats Ani! Excited to see all that you will accomplish.

Cascade screening of first-degree relatives of individuals with high lipoprotein(a) levels, if implemented at scale, is likely to identify a substantial number of additional high-risk individuals. ja.ma/47WW0XM

Some good stuff on IG (instagram.com/ourhealthstudy) all #HeartMonth! 💜 👀check us out, 👍follow us, 🗣️spread the word, and 🧑‍💻sign up! ourhealthstudy.org

UPenn Lipid Clinic - we're hiring clinical research coordinators. Great experience for future med school applicants. If you know a motivated candidate, they can apply here: wd1.myworkdaysite.com/recruiting/upe…

Join Lpa Forum for free, peer-reviewed information about #Lpa – an independent risk factor for #heartdisease, even when #cholesterol levels are low. Find out why experts are so interested & what treatments are in the pipeline > lpaforum.org #cardioTwitter #lipidTwitter

Lpa Forum benefits from a distinguished, international committee of experts, who will openly present and discuss their insights into new findings in the field of #Lipoproteina. Join now to stay up to date in this exciting field > lpaforum.org #LPA

Congratulations Veeral Ajmera - strong work MASLD Research Center UCSD Gastroenterology !

Introducing Marea - a clinical-stage biotech on a mission to leverage large-scale human genetics and adipose biology to revolutionize the treatment of #cardiometabolic diseases. Learn more: businesswire.com/news/home/2024…

How does a polygenic risk score for obesity (BMI) interact with 5 lifestyle factors for outcomes in >330,000 UK Biobank participants ? cell.com/cell-metabolis… Cell Metabolism Min Seo Kim, MD, MSs Amit V. Khera Injeong Shim Akl Fahed Pradeep Natarajan Ron Do

The authors report that adherence to a healthy lifestyle (minimal obesogenic behaviors) is associated with a reduced risk of #obesity and obesity-related morbidities Cell Metabolism Can you outrun your #Genetics cell.com/cell-metabolis…

A wonderful look at the future and the power of believing there is a new way of #CVPrev! Thank you Verve Therapeutics Sek Kathiresan MD et al for sharing the excitement with us today ASPC Dr. Payal Kohli, MD

Tomorrow is the last day to submit nominations for the Douglas P. Zipes Distinguished Young Scientist Award! This award recognizes young physician scientists who have made contributions to the field of CVD & have an impressive body of scientific research. bit.ly/3wp12d7

Ready to make your next career move? We are looking to add a Senior Scientist, Toxicologist to our growing team. Learn more from hiring manager Kim Pendino and check out the role here: vervetx.com/open-positions…

Today, we announced pipeline progress and earnings from Q2 2024 including updates on the Heart-2 clinical trial of VERVE-102, Phase 1b clinical trial initiation for VERVE-201 and more. Read the full announcement here: ir.vervetx.com/news-releases/…

2Q Earnings Verve Therapeutics Continued progress: 1. Heart-2 trial testing VERVE-102 is enrolling 2. Heart-2 and PCSK9 program data update planned for first half of 2025 3. $576M in cash, runway into late 2026 4. Rest of cholesterol-lowering pipeline (VERVE-201 targeting ANGPTL3